Related Experiment Videos
Vaccination against strontium-90-induced bone tumors
Journal of the National Cancer Institute
|September 1, 1983
Summary
Immunization against osteosarcoma virus delayed, but did not prevent, bone tumors in mice treated with 90Sr. Active virus, however, significantly increased tumor incidence, indicating a potential role for viral activity in bone cancer development.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Strontium-90 (90Sr) is a known inducer of bone tumors.
- Osteosarcoma virus is implicated in the development of bone cancers.
- Investigating preventative strategies against radiation-induced bone tumors is crucial.
Purpose of the Study:
- To determine if immunization against a murine osteosarcoma virus can reduce the incidence of bone tumors induced by 90Sr.
- To evaluate the effect of active FBJ virus on bone tumor development in the presence of 90Sr exposure.
Main Methods:
- 190 female C57BL/6J mice were divided into control and experimental groups.
- Mice received 1.0 μCi of 90Sr at 66 days of age.
- Experimental groups were vaccinated with inactivated FBJ osteosarcoma virus or injected with active FBJ virus.
Main Results:
- Vaccination with inactivated virus significantly reduced bone tumor deaths within the first 600 days post-irradiation (P < .01).
- Lifetime incidence of bone tumors was not significantly different between vaccinated and control groups (P = .07), suggesting delayed tumor development.
- Injection of active FBJ virus significantly increased lifetime bone tumor incidence in 90Sr-treated mice (P = .01).
Conclusions:
- Immunization against murine osteosarcoma virus can delay the onset of 90Sr-induced bone tumors.
- Active FBJ virus exacerbates bone tumor development when combined with 90Sr exposure.
- These findings highlight the complex interplay between viral agents and radiation in osteosarcoma pathogenesis.